HomeProductsBioactive CompoundsProtein Kinase TargetsTAM ReceptorDubermatinib
Chemical structure of CAS 1341200-45-0

Dubermatinib

CAS No.1341200-45-0
MDL No.MFCD28502172
MFC24H30ClN7O2S
MW516.10
InChI KeyYUAALFPUEOYPNX-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1341200-45-0
Product NameDubermatinib

Associated Conditions

neoplasm·chronic lymphocytic leukemia·acute myeloid leukemia
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

TP-0903 is active in models of drug-resistant acute myeloid leukemia.

JCI insight • Vol. 5, Issue 23 • 2020
PMID: 33268594PMC: PMC7714403DOI: 10.1172/jci.insight.140169

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020
PMID: 32020584PMC: PMC7160657DOI: 10.1111/imm.13175

Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy.

Oncotarget • Vol. 9, Issue 98 • 2018
PMID: 30647852PMC: PMC6324680DOI: 10.18632/oncotarget.26444

Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia.

Leukemia & lymphoma • Vol. 57, Issue 6 • 2016
PMID: 26440741PMC: PMC4963009DOI: 10.3109/10428194.2015.1102243

Documentation